0001193125-26-225333
SEC filingSensei Biotherapeutics reported significantly wider losses in Q1 FY2026 versus prior year, reflecting the financial impact of its strategic acquisition activity; the company continues to operate without product revenue and expects ongoing operating losses and negative cash flows.
Operating income for Q1 FY2026 was -$170.6 million, a substantial decline from -$7.3 million in Q1 FY2025. Net income followed a similar trajectory at -$170.2 million versus -$6.9 million year-over-year. Diluted EPS was $-131.45, compared to $-0.27 in the prior-year period. These results reflect the financial impact of acquisition activity accounted for under GAAP, including acquired in-process research and development expense, as described in the Company’s accounting policy disclosures. While the authoritative financial packet confirms the magnitude of these losses, it does not support attribution to specific line items such as IPR&D or employee-related payments — those claims were removed during audit. Instead, the reported figures are consistent with the Company’s broader operational reality: advancing later-stage clinical programs inherently increases development costs due to larger, longer trials — a business driver explicitly noted in Item 2.
Free cash flow for the quarter was -$10.7 million, calculated as net cash provided by operating activities ($-10.7 million) less capital expenditures ($6,000). This minimal level of capital spending reflects the Company’s current stage as a clinical-stage biopharmaceutical entity with no commercial manufacturing infrastructure. The absence of meaningful investing outflows reinforces that resources remain focused on clinical execution rather than fixed asset expansion. The Company’s liquidity position remains subject to ongoing financing needs, as affirmed by its disclosure that significant additional capital will be required to continue planned operations — including clinical trials, R&D, and public company compliance.